-
British Journal of Industrial Medicine Jan 197056-60. A case of acute arsine poisoning is described, occurring in an industrial metallurgy worker. The clinical course was of associated oliguric renal failure with...
56-60. A case of acute arsine poisoning is described, occurring in an industrial metallurgy worker. The clinical course was of associated oliguric renal failure with acute haemolytic anaemia which was self-limiting but accompanied by marked non-thrombotic phlebitis. There was minor hepatocellular damage. Skin pigmentation was disproportionate to the elevation of serum bilirubin. Transient initial pulmonary oedema was regarded as a local irritative phenomenon. All systems underwent complete recovery. Renal function in particular was explored in all modalities, and no abnormality could be found in glomerular filtration, concentrating power or acidification 12 months after exposure. There was no proteinuria. The clinical picture was of acute tubular necrosis, although interstitial fibrosis was present and its incomplete final resolution is possible. Contrary to the findings of other workers, no evidence was found of myocardial damage at any stage either clinically or electrocardiographically.
Topics: Acute Kidney Injury; Anemia, Hemolytic; Arsenic Poisoning; Blood Urea Nitrogen; Follow-Up Studies; Humans; Hyperbilirubinemia; Kidney; Kidney Concentrating Ability; Male; Metallurgy; Middle Aged; Occupational Diseases; Phlebitis; Pigmentation; Proteinuria; Pulmonary Edema
PubMed: 5418920
DOI: 10.1136/oem.27.1.56 -
Balkan Medical Journal Jul 2022
Topics: Humans; Thrombophlebitis
PubMed: 35674503
DOI: 10.4274/balkanmedj.galenos.2022.2022-3-60 -
Cleveland Clinic Journal of Medicine Jul 2022
Topics: Breast; Humans; Thrombophlebitis
PubMed: 35777840
DOI: 10.3949/ccjm.89a.21097 -
BMJ (Clinical Research Ed.) Jan 1996
Topics: Humans; Phlebitis; Risk Factors; Thrombophlebitis; Varicose Veins
PubMed: 8563576
DOI: 10.1136/bmj.312.7025.198 -
International Journal of Nursing Studies Dec 2021Peripheral intravenous catheters are an essential medical device which are prone to complications and failure.
BACKGROUND
Peripheral intravenous catheters are an essential medical device which are prone to complications and failure.
OBJECTIVES
Identify patient, provider and device risk factors associated with all-cause peripheral intravenous catheter failure as well as individual complications: phlebitis, infiltration/occlusion, and dislodgement to improve patient outcomes.
DESIGN
Secondary analysis of twelve prospective studies performed between 2008 and 2020.
SETTINGS
Australian metropolitan and regional hospitals including one paediatric hospital.
PARTICIPANTS
Participants were from medical, surgical, haematology, and oncology units.
METHODS
Multilevel mixed-effects parametric survival regression was used to identify factors associated with all-cause peripheral intravenous catheter failure, phlebitis, occlusion/infiltration, and dislodgement. We studied patient (e.g., age, gender), device (e.g., gauge), and provider (e.g., inserting clinician) variables. Stepwise regression involved clinically and p<0.20 significant variables entered into the multivariable model. Results were expressed as hazard ratios (HRs) and 95% confidence intervals (CI); p<0.01 was considered statistically significant.
RESULTS
Of 11,830 peripheral intravenous catheters (8,200 participants) failure occurred in 36% (n = 4,263). Occlusion/infiltration incidence was 23% (n = 2,767), phlebitis 12% (n = 1,421), and dislodgement 7% (n = 779) of catheters. Patient factors significantly associated with failure and complications were: female gender (phlebitis; (HR 1.98, 95% CI 1.72-2.27), (infiltration/occlusion; HR 1.45, 95% CI 1.33-1.58), (failure; HR 1.36, 95% CI 1.26-1.46); and each year increase in age (phlebitis; 0.99 HR, 95% CI 0.98-0.99), (failure; 0.99 HR, 95% CI 0.99-0.99). The strongest provider risk factor was intravenous antibiotics (infiltration/occlusion; HR 1.40, 95% CI 1.27-1.53), (phlebitis; HR 1.36, 95% CI 1.18-1.56), (failure; HR 1.26, 95% CI 1.17-1.36). Catheters inserted by vascular access teams were less likely to dislodge (HR 0.53, 95% CI 0.42-0.67). Device risk factors most associated with all-cause failure were wrist/hand (HR 1.34, 95% CI 1.23-1.46), antecubital fossa peripheral intravenous catheters (HR 1.29, 95% CI 1.16-1.44) and 22/24 gauge (HR 1.27, 95% CI 1.12-1.45) catheters.
CONCLUSION
Factors identified, including the protective aspect of vascular access team insertion, and high catheter failure associated with intravenous antibiotic administration, will allow targeted updates of peripheral intravenous catheter guidelines and models of care.
Topics: Australia; Catheterization, Peripheral; Catheters; Child; Female; Humans; Phlebitis; Prospective Studies
PubMed: 34689013
DOI: 10.1016/j.ijnurstu.2021.104095 -
Immunity, Inflammation and Disease Nov 2023Amiodarone (AM) is a drug commonly used in patients with ventricular arrhythmias. It can damage vascular endothelial cells and easily cause phlebitis. At present, the...
OBJECTIVE
Amiodarone (AM) is a drug commonly used in patients with ventricular arrhythmias. It can damage vascular endothelial cells and easily cause phlebitis. At present, the prevention and treatment of phlebitis induced by the use of AM is not clear due to the lack of corresponding primary research. Isoliquiritigenin (ISL) has an anti-inflammatory effect, but until now, has not been explored much in the field of research in primary care nursing. The purpose of this study is to investigate the efficacy and mechanism of action of ISL in treating phlebitis induced by AM.
METHODS
In our study, we used human umbilical vein endothelial cells (HUVECs) that were divided into three groups: the NC group (normal), the AM group (AM 30 μmol/L for 24 h), and the ISL pretreatment group (isoliquiritigenin 10 μmol/L after 1 h of pretreatment with amiodarone for 24 h). We used CCK-8 to detect cell proliferation, cell scratch assay to detect the migration capability of cells, flow cytometry to measure apoptosis, angiogenesis assay to check the total length and total branches of angiogenesis, and PCR and WB to detect the expression of PCNA, casepase-3, and VEGFA. WB was used to detect NF-κBp65 and p-NF-κBp65 expression.
RESULTS
Compared with the AM group, the ISL pretreatment promoted cell proliferation and migration, inhibited cell apoptosis, increased the total length and total branches of angiogenesis, and downregulated p-NF-κBp65 expression.
CONCLUSION
ISL shows promise in the prevention and treatment of clinical phlebitis and can be used as a potential therapeutic drug to prevent phlebitis.
Topics: Humans; Human Umbilical Vein Endothelial Cells; Amiodarone; Chalcones; Phlebitis
PubMed: 38018585
DOI: 10.1002/iid3.1094 -
Phlebology Feb 2023Varicose veins (VV) negatively impact quality of life (QoL) and have risks of major complications including bleeding, ulceration and phlebitis. During the COVID-19...
INTRODUCTION
Varicose veins (VV) negatively impact quality of life (QoL) and have risks of major complications including bleeding, ulceration and phlebitis. During the COVID-19 pandemic, the VSGBI (Vascular Society of Great Britain and Ireland) and GIRFT (Get It Right First Time) classified VVs as lowest priority for intervention.
OBJECTIVE
This study aims to determine harm caused and the impact on the QoL on patients waiting for their VVs procedures for more than 1 year.
METHODS
This was a prospective study conducted at the Norfolk and Norwich University Hospital (NNUH). Patients with VVs awaiting intervention for >1 year were included in the study. Patients with CEAP C6 disease were considered to be too high risk to be invited for treatment during the Covid-19 pandemic. Patients were sent QoL questionnaires and underwent a telephone consultation to assess harm. Both generic (EQ-VAS and EQ-5D) and disease-specific (AVVQ and CIVIQ-14) instruments were utilised. There were no control groups available for comparison.
RESULTS
275 patients were identified (37.1% male) with median time on waiting list of 60 weeks (IQR 56-65). 19 patients (6.9%) came to major harm, including phlebitis (3.6%), bleeding (1.8%) and ulceration (1.8%). Fifty-two patients (18.9%) had minor harm, including worsening pain (12.7%) and swelling (6.2%). 6.9% reported psychological harm. Rising CEAP stage was also associated with worsening level of harm in patients with C5-6 disease ( < 0.0001). Only 8.7% stated they would decline surgery during the pandemic. 104 QoL questionnaires were returned. Median EQ-VAS and EQ-5D was 75 (IQR: 60-85) and 0.685 (0.566-0.761), respectively. Median AVVQ score was 23.2 (14.9-31.0) and CIVIQ-14 score was 33 (21-44).ConclusionsThis study highlights the impact of delaying VVs surgery during a pandemic. A significant rate of both major and minor as well as psychological harm was reported. In addition, VVs had a significant detriment to quality of life.
Topics: Humans; Male; Female; Quality of Life; Pandemics; Prospective Studies; Referral and Consultation; COVID-19; Telephone; Varicose Veins; Surveys and Questionnaires; Phlebitis; Treatment Outcome
PubMed: 36441941
DOI: 10.1177/02683555221141824 -
Internal Medicine (Tokyo, Japan) May 2021
Topics: Humans; Leg; Thrombophlebitis
PubMed: 33229811
DOI: 10.2169/internalmedicine.6102-20 -
Annals of the Royal College of Surgeons... Jul 1967
Topics: Fibrinolysis; Fibrinolytic Agents; Humans; Thrombophlebitis
PubMed: 4951632
DOI: No ID Found -
British Medical Journal Nov 1972
Topics: Abortion, Therapeutic; Contraceptive Agents; Diarrhea; Fatty Acids, Essential; Female; Headache; Humans; Labor, Induced; Male; Nausea; Phlebitis; Pregnancy; Prostaglandins; Vomiting
PubMed: 4637516
DOI: No ID Found